喹硫平(35例)与氯丙嗪(34例)治疗精神分裂症的比较

目的 :比较喹硫平与氯丙嗪治疗精神分裂症的疗效及不良反应。方法 :6 9例病人分 2组。喹硫平组 35例 (男性 18例 ,女性 17例 )给予喹硫平 ;氯丙嗪组 34例 (男性 19例 ,女性 15例 )给予氯丙嗪 ,2药剂量均为 2 0 0～ 6 0 0mg·d- 1,分 2次服 ;疗程12wk ;用阳性与阴性症状量表 (PANSS)评定临床疗效 ,用不良反应量表 (TESS)评定药物不良反应。结果 :喹硫平组有效率 6 6 % ;氯丙嗪组有效率 6 5 %(P >0 .0 5 ) ,氯丙嗪组的不良反应较多。结论 :喹硫平治疗精神分裂症安全有效 ,疗效与氯丙嗪相似 ,不良反应较少。

Quetiapine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia

AIM: To compare the therapeutic efficacy and adverse reactions of quetiapine and chlorpromazine in the treatment of schizophrenia. METHODS: Sixty-nine patients were divided into two groups: quetiapine-treated group (n=35; M 18, F 17) and chlorpromazine-treated group (n=34; M 19, F15). The dosage of drug administration in two groups was both 200-600 mg·d -1 and the treatment duration was 12 wk. The efficacy and adverse reactions were assessed by the PANSS and TESS, respectively. RESULTS: The clinical effective rate was 66 % in quetapine group and 65 % in chlorpromazine group, there was no significant difference between two groups (P>0.05). But compared with quetiapine group, the adverse reactions in chlorpromazine group occurred more often. CONCLUSION: The clinical efficacy of quetiapine and chlorpromazine in treating schizophrenia is similar, and adverse reactions of the former are lower than that of the latter.